健友股份子公司获得美国FDA醋酸奥曲肽注射液药品增加生产场地注册批件

Core Viewpoint - The company announced that its subsidiary, Meitheal Pharmaceuticals, Inc., received approval from the U.S. FDA for the production of Acetate Octreotide Injection in various concentrations, which is expected to positively impact the company's financial performance [1] Group 1 - The FDA approval includes the production of Acetate Octreotide Injection at concentrations of 50 mcg/mL, 100 mcg/mL, and 500 mcg/mL [1] - The approved product will soon be launched in the U.S. market [1] - The production will take place at the Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. facility [1]